Effects of cisapride on gastrointestinal motor activity and gastric emptying of disopyramide.
The effects of cisapride on the gastrointestinal contractile activity and pharmacokinetics of disopyramide were determined in beagle dogs and patients with arrhythmia. In the animal experiments, the gastric motor index was significantly decreased by i.v. administration of disopyramide in a dose-dependent fashion. The peak decrease of the motor index was observed within 5 min after i.v. injection of disopyramide; the motor index then recovered gradually to the level present prior to drug administration. I.v. administration of cisapride (0.5 mg/kg) markedly increased gastrointestinal contractile activity following the decrease induced by disopyramide pretreatment (5 mg/kg, i.v.). In the clinical studies, the gastric emptying test was performed using the acetaminophen method. A significant correlation between plasma concentrations of disopyramide and gastric emptying time has been found (p < 0.001). The combination of disopyramide (100 mg t.i.d.) and cisapride (2.5 mg t.i.d.) significantly increased gastric emptying compared with that induced by disopyramide alone. The peak plasma concentration of disopyramide in association with cisapride oral administration was significantly higher, and the apparent absorption rate constant and lag time of disopyramide were about 2-fold higher and 2-fold shorter, respectively, than for disopyramide alone. Cisapride, acting as a cholinergic agonist, may counteract the anticholinergic effect of disopyramide on gastric motility. As a factor influencing drug absorption, gastric emptying is of importance, as it determines the rate of drug delivery to the small intestine. Therefore, the oral administration of disopyramide with cisapride may be useful for patients with delayed gastric emptying.
Kuroda
T
T
Department of Hospital Pharmacy, Miki City Hospital, Japan.
Yoshihara
Y
Y
Nakamura
H
H
Azumi
T
T
Inatome
T
T
Fukuzaki
H
H
Takanashi
H
H
Yogo
K
K
Akima
M
M
D000284:Administration, Oral; D000818:Animals; D001145:Arrhythmias, Cardiac / Q000503:physiopathology*; D020117:Cisapride; D004206:Disopyramide / Q000097:blood / Q000493:pharmacokinetics* / Q000494:pharmacology; D004285:Dogs; D004357:Drug Synergism; D005260:Female; D005746:Gastric Emptying / Q000187:drug effects*; D005769:Gastrointestinal Motility / Q000187:drug effects*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000008:administration & dosage / Q000494:pharmacology*; D012702:Serotonin Antagonists / Q000494:pharmacology*
D010880:Piperidines; D012702:Serotonin Antagonists; D004206:Disopyramide; D020117:Cisapride